NEW YORK, Feb. 9, 2015 /PRNewswire/ -- Lightlake
Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical
company developing addiction treatments based on its expertise in
opioid antagonists, announced today that Arvind Agrawal has joined Lightlake as Executive
Vice President, Medical Affairs, effective January 2015.
Mr. Agrawal brings over 20 years of experience in medical and
public affairs, scientific communications, and clinical development
to Lightlake. During his career, Mr. Agrawal has overseen, managed,
and delivered global phase I-IV clinical studies and has extensive
experience in the therapeutic areas of addiction, psychiatry, CNS,
respiratory, cardiovascular, and diabetes.
Prior to joining Lightlake, Mr. Agrawal was Head of Medical
Affairs New Products at Mundipharma International, where he made
significant advances in the development of a novel treatment for
opioid addiction.
As European Clinical and Scientific Affairs Director of Reckitt
Benckiser Pharmaceuticals, he developed successful strategies
leading to highly positive clinical, public, and legislative
changes for the cost-effective treatment of opioid dependence.
Mr. Agrawal served three years at AstraZeneca plc as European
Medical Affairs Manager prior to joining Reckitt Benckiser
Pharmaceuticals. Managing a large team of medical managers from
across Europe, he was responsible
for the lifecycle management of late-stage development and marketed
products and communicated new clinical data to a large community of
stakeholders.
Prior to his appointment at AstraZeneca plc as European Medical
Affairs Manager, Mr. Agrawal served as a Therapy Area Specialist
and Clinical Study Manager at AstraZeneca plc and a Medical Affairs
Manager for GlaxoSmithKline plc, SmithKline Beecham plc, and
Wellcome Pharmaceuticals, where he helped to launch pharmaceutical
blockbusters Crestor (rosuvastatin) and Avandia
(rosiglitazone).
Arvind Agrawal holds a MSc in
Human & Applied Physiology from King's College, University of
London, and serves as the Managing
Director of Ekagra Ltd., a pharmaceutical medical affairs
consultancy based in the United
Kingdom.
"We are delighted to announce Arvind
Agrawal has joined the Company as EVP, Medical Affairs,"
stated Dr. Roger Crystal, CEO of
Lightlake. He added, "Arvind brings an extensive and impressive
background in medical and clinical affairs, having worked with key
global regulatory authorities. He joins us at an ideal time to lead
our medical and clinical affairs as we advance our clinical trials
and move our product pipeline forward now that we have partnered
with Adapt Pharma Limited on our opioid overdose reversal
product."
In December 2014, Lightlake
announced a licensing deal with a subsidiary of Adapt Pharma
Limited. In exchange for licensing its opioid overdose reversal
treatment, Lightlake could receive potential development and sales
milestone payments of more than $55
million, plus up to double-digit royalties.
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc., a biopharmaceutical company, is
using its expertise in opioid antagonists to build a platform of
innovative intranasal naloxone solutions to common addictions and
related disorders. Lightlake is developing a treatment to reverse
opioid overdoses, which have reached epidemic proportions in
the United States. Lightlake has
collaborated on clinical trials with the National Institute on Drug
Abuse, part of the National Institutes of Health, and has entered
into a licensing deal with a subsidiary of Adapt Pharma Limited.
Lightlake also has completed a Phase II clinical trial to treat
Binge Eating Disorder. For more information please visit:
http://www.lightlaketherapeutics.com
(http://www.lightlaketherapeutics.com/).
Forward-Looking Statements
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," "estimates," "predicts," "projects,"
"potential," or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward-looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
press release to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
News Release
Corporate Contact:
Lightlake Therapeutics Inc.
445 Park Avenue, 9th Floor
New York, NY 10022
Dr. Roger Crystal, CEO
212-829-5546
investor.relations@lightlaketherapeutics.com
Investor Relations Contact:
Amato and Partners, LLC
admin@amatoandpartners.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lightlake-therapeutics-inc-announces-arvind-agrawal-appointed-executive-vice-president-medical-affairs-300032605.html
SOURCE Lightlake Therapeutics Inc.